Pension plans dally with biotech

Article Abstract:

The pension managers are reluctant to invest huge sums of money in biotech private equity, but might be warming up to the idea that the high rewards that come from investing in mid-stage biotech companies might justify the high risk these investments typically entail. That change in attitude could become a boon for early-stage biotech companies that do not have other sources of financing, especially in countries like Australia or Canada.

Australia, Canada, Pension, health, and welfare funds, Pension Funds & Benefit Plans, Pension Funds

---

Goodbye Columbus! New NRDOs forego discovery

Article Abstract:

The NRDOs, are companies that bypass the expensive and risky business of discovering novel molecules and instead concentrate on developing assets they have in-licensed, having investors like venture capitalists. Some NRDOs ultimately move to discovery if the risk/reward ratio of in licensing looks less appealing in the future.

Investor relations

---

Tobacco money reinvested in biotech

Article Abstract:

BoiAdvance, a biotech support initiative based in Philadelphia, announced the name of the emerging companies due to benefit from seed and early stage financing from its '2005 Greenhouse Fund'. BioAdvance is one of three Pennsylvania-based greenhouse initiatives endowed with a total of $100 million of tobacco settlement funds.

BioAdvance

Similar abstracts:

• Abstracts: Air Force needs tanker plane serving multiple roles. Sambur defends Raptor, tanker need, and his record. General: Air Force not lacking tankers in Iraq; C-130Js 'wonderful'
• Abstracts: HDAC inhibitors overcome first hurdle. New apoptosis drugs face critical test
• Abstracts: First-in-class biologic to enter rheumatoid arthritis fray. Hepatitis C: staying the course
• Abstracts: Mind the (biomedical funding) gap. The importance of angels in starting a US biotech venture. Biotech venture capital-it's not too late to be early
• Abstracts: Protein biomarker discovery and validation: The long and uncertain path to clinical utility. Serum proteomics profiling- a young technology begins to mature

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.